Skip to main content
Figure 2 | Journal of Pharmaceutical Health Care and Sciences

Figure 2

From: Correlation of plasma crizotinib trough concentration with adverse events in patients with anaplastic lymphoma kinase positive non-small-cell lung cancer

Figure 2

The cumulative numbers of adverse events in the higher and in the lower crizotinib trough concentration groups. The crizotinib trough concentration is divided into a higher trough concentration group (n = 5, −−−−−−−) and a lower trough concentration group (n = 4, −------) delimited at the median concentration (508.5 ng/mL). Adverse events were evaluated four times (day 7, 14, 21, and 28).

Back to article page